Remicade vs. Humira comparison
Remicade (infliximab) and Humira (adalimumab) are both laboratory-synthesized proteins. They are different chemicals on a molecular level, but they are designed to do the same thing: block a specific immune antibody that causes inflammation in a half-dozen different autoimmune disorders, including rheumatoid arthritis.
The side effects common to both Remicade and Humira include:
The chief worry for a patient taking these injections, however, is the risk of a bacterial or fungal infection. After all, the express goal of both Remicade and Humira is to suppress the immune system.
This helps control the symptoms of autoimmune disorders, but also decreases your
body’s ability to fight infections.
What are Remicade and Humira?
Remicade and Humira are injectable monoclonal antibodies (a type of synthesized protein made from cells in a lab) in the class of medications called TNF blockers or TNF inhibitors. This class also includes:
In autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis and the other conditions Remicade and Humira are approved to treat, the immune system mistakes the body's own cells for foreign ones and attacks them, causing inflammation, pain, tissue destruction and other associated symptoms.
TNF alpha (tumor necrosis factor alpha) is one of a number of different antibodies produced by white blood cells and other parts of the immune system. TNF alpha plays an important role in coordinating immune attacks on foreign invaders in the body, like viruses or bacteria. In the case of the disorders in question, the victims of the destruction initiated and controlled by TNF alpha are the body's own tissues.
Remicade, Humira and the other members of the TNF inhibitor class are different types of protein molecules all designed to achieve the same goal: binding to the TNF alpha molecules to render them harmless, thereby reducing inflammation, whether it's in the joints, skin, or bowels.
Neither Remicade nor Humira can cure any of the diseases for which they're approved as treatment, but each medication can dramatically reduce the symptoms, such as joint pain. Furthermore, in rheumatoid arthritis, infliximab and adalimumab can slow damage to the joint. Because both of these biologically derived medications (biologic drugs) modify the course of the disease in addition to alleviating symptoms, they are known as "disease-modifying anti-rheumatic drugs" or DMARDs.
Sometimes, infliximab or adalimumab are used in conjunction with other DMARDs that work by different mechanisms, such as Methotrexate (Rheumatrex). Methotrexate is an antimetabolite that interferes with cell function rather than blocking a specific antibody as infliximab and adalimumab do.
What are the uses for Remicade and Humira?
Doctors prescribe infliximab and adalimumab for treatment of the following conditions:
- rheumatoid arthritis,
- psoriatic arthritis,
- ankylosing spondylitis,
- plaque psoriasis,
- juvenile idiopathic arthritis, and
- Crohn’s disease
Latest Arthritis News
- COVID Antiviral Pill Approval
- Are Diet Drinks Any Better?
- Diabetes Ups Alzheimer’s Risk
- Key Protein in TBI Patients
- Breastfeeding Helps Postpartum Depression
- More Health News »
Trending on MedicineNet
- Breast Cancer Warning Signs
- CMT Disease
- Main Cause of Graves’ Disease
- RSV in Adults
- Ehlers-Danlos Syndrome
Which drugs interact with Remicade and Humira?
Some vaccines contain living bacteria and active viruses to condition the immune reaction. Doctors should never administer these vaccines to people taking either Remicade or Humira because of the infection risk.
Combination of Remicade and Humira with other, non biologic DMARDs like methotrexate can increase the symptom relief over prescribing either drug alone. Doctors, therefore, frequently prescribe TNF inhibitors and non biologic DMARDs in tandem.
Are Remicade and Humira safe to take during pregnancy or while breastfeeding?
In the absence of research, doctors must weigh the risks and benefits before prescribing Remicade or Humira to pregnant or breastfeeding mothers.
Because of the potential immune suppression effects, however, the prescribing information recommends against administering live vaccines to a baby within six months of being exposed to a TNF inhibitor.